• If you are wondering whether CRISPR Therapeutics at around US$52 per share looks like an opportunity or a stock to be cautious on, the key is understanding what that price actually builds in.
• The stock has delivered a 58.0% return over the last year, even though the year to date return is slightly negative at 2.6%, with shorter term moves of 0.6% over 7 days and 5.8% over 30 days adding extra noise on top.
• Recent headlines around CRISPR Therapeutics have focused on its gene editing platform and pipeline progress, which often shape how investors think about future potential and risk. These kinds of updates can help explain why the stock price has moved more over a 1 year period than in the very short term.
• Against that backdrop, the company currently has a value score of 3 out of 6. The rest of this article will unpack what that means across different valuation approaches, and then finish with a wider lens on how to think about CRISPR Therapeutics' value in context.

Approach 1: CRISPR Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of a company’s future cash flows and discounts them back to today using a required rate of return, to arrive at an estimated intrinsic value per share.

For CRISPR Therapeutics, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow stands at a loss of about $345.4 million. Analyst and extrapolated projections in the model show free cash flow staying negative in the nearer years, then turning positive and reaching $214.5 million by 2030. Beyond the first few analyst covered years, Simply Wall St extends the cash flow path using its own assumptions.

Putting all projected cash flows together and discounting them to today gives an estimated intrinsic value of about $202.60 per share. Versus a share price around $52, this implies a very large valuation gap. On these inputs, the DCF output indicates the stock is 74.1% undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests CRISPR Therapeutics is undervalued by 74.1%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: CRISPR Therapeutics Price vs Book

For companies that are not yet profitable but have significant assets on the balance sheet, the price to book, or P/B, ratio is often a useful cross check on valuation because it compares what you pay in the market with the accounting value of net assets.

In general, higher growth expectations or lower perceived risk can support a higher P/B multiple, while slower growth prospects or higher risk tend to justify a lower one. So context really matters when you look at where a stock trades relative to its book value.

CRISPR Therapeutics currently trades on a P/B of about 2.63x. This sits slightly above the Biotechs industry average P/B of about 2.31x, and below the peer group average of about 6.29x. Simply Wall St also uses a proprietary “Fair Ratio” which estimates what a reasonable P/B could be for CRISPR Therapeutics based on factors such as its earnings profile, industry, profit margins, market cap and risk characteristics.

Compared with simple peer or industry comparisons, the Fair Ratio aims to give a more tailored view because it adjusts for company specific drivers rather than assuming all biotechs should trade on the same multiple.

Without a specific Fair Ratio figure, it is not possible to categorise the stock as overvalued, undervalued or about right on this metric alone.

Result: ABOUT RIGHT

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your CRISPR Therapeutics Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as a simple story that you attach to your numbers, where you spell out how you think CRISPR Therapeutics' revenue, earnings and margins could evolve, and what fair value that points to.

A Narrative ties together three pieces: your view of the company’s story, the financial forecast that fits that story, and the fair value that follows from those assumptions.

On Simply Wall St’s Community page, Narratives are presented as an easy tool used by millions of investors, helping you compare your own fair value with the current market price so you can decide if CRISPR Therapeutics looks attractive or stretched on your assumptions. They update automatically when new information such as earnings or major news is added to the platform.

For example, some investors on the Community page might build a Narrative for CRISPR Therapeutics with a very optimistic fair value and strong margin assumptions. Others may set a much lower fair value with more conservative revenue and profit expectations, all using the same framework but different stories.

Do you think there's more to the story for CRISPR Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.